Glükokortikoid-indukált osteoporosis.

Translated title of the contribution: Glucocorticoid-induced osteoporosis

M. Tóth, Z. Tulassay

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Chronic glucocorticoid treatment is the most frequent cause of secondary osteoporosis. The direct inhibitory effect of glucocorticoids on osteoblasts results in decreased bone formation. Increased osteoclastic bone resorption due to low concentrations of gonadal steroid hormones and glucocorticoid-induced direct suppression of intestinal calcium absorption also contribute to the decrease of bone mass in these patients. Bone loss is rapid, particularly in the first months of glucocorticoid therapy. Bone mineral density of the lumbar spine and proximal femur should be measured in patients who are starting chronic therapy with glucocorticoids. Although glucocorticoid-induced osteoporosis is a severe and nowadays partially preventable disorder, osteoporosis prophylaxis is only rarely prescribed to these patients. Recent randomized, controlled trials proved the therapeutic effects of hormone replacement therapy, as well as of bisphosphonates and active vitamin D analogs in primary and secondary prevention of glucocorticoid-induced osteoporosis.

Original languageHungarian
Pages (from-to)219-223
Number of pages5
JournalOrvosi Hetilap
Volume141
Issue number5
Publication statusPublished - Jan 30 2000

Fingerprint

Glucocorticoids
Osteoporosis
Bone and Bones
Hormone Replacement Therapy
Intestinal Absorption
Diphosphonates
Gonadal Steroid Hormones
Therapeutic Uses
Primary Prevention
Bone Resorption
Secondary Prevention
Osteoblasts
Osteogenesis
Vitamin D
Bone Density
Femur
Spine
Therapeutics
Randomized Controlled Trials
Calcium

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Glükokortikoid-indukált osteoporosis. / Tóth, M.; Tulassay, Z.

In: Orvosi Hetilap, Vol. 141, No. 5, 30.01.2000, p. 219-223.

Research output: Contribution to journalArticle

Tóth, M & Tulassay, Z 2000, 'Glükokortikoid-indukált osteoporosis.', Orvosi Hetilap, vol. 141, no. 5, pp. 219-223.
Tóth, M. ; Tulassay, Z. / Glükokortikoid-indukált osteoporosis. In: Orvosi Hetilap. 2000 ; Vol. 141, No. 5. pp. 219-223.
@article{1ecc3b6cff064533abf05fbb90cf6b46,
title = "Gl{\"u}kokortikoid-induk{\'a}lt osteoporosis.",
abstract = "Chronic glucocorticoid treatment is the most frequent cause of secondary osteoporosis. The direct inhibitory effect of glucocorticoids on osteoblasts results in decreased bone formation. Increased osteoclastic bone resorption due to low concentrations of gonadal steroid hormones and glucocorticoid-induced direct suppression of intestinal calcium absorption also contribute to the decrease of bone mass in these patients. Bone loss is rapid, particularly in the first months of glucocorticoid therapy. Bone mineral density of the lumbar spine and proximal femur should be measured in patients who are starting chronic therapy with glucocorticoids. Although glucocorticoid-induced osteoporosis is a severe and nowadays partially preventable disorder, osteoporosis prophylaxis is only rarely prescribed to these patients. Recent randomized, controlled trials proved the therapeutic effects of hormone replacement therapy, as well as of bisphosphonates and active vitamin D analogs in primary and secondary prevention of glucocorticoid-induced osteoporosis.",
author = "M. T{\'o}th and Z. Tulassay",
year = "2000",
month = "1",
day = "30",
language = "Hungarian",
volume = "141",
pages = "219--223",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "5",

}

TY - JOUR

T1 - Glükokortikoid-indukált osteoporosis.

AU - Tóth, M.

AU - Tulassay, Z.

PY - 2000/1/30

Y1 - 2000/1/30

N2 - Chronic glucocorticoid treatment is the most frequent cause of secondary osteoporosis. The direct inhibitory effect of glucocorticoids on osteoblasts results in decreased bone formation. Increased osteoclastic bone resorption due to low concentrations of gonadal steroid hormones and glucocorticoid-induced direct suppression of intestinal calcium absorption also contribute to the decrease of bone mass in these patients. Bone loss is rapid, particularly in the first months of glucocorticoid therapy. Bone mineral density of the lumbar spine and proximal femur should be measured in patients who are starting chronic therapy with glucocorticoids. Although glucocorticoid-induced osteoporosis is a severe and nowadays partially preventable disorder, osteoporosis prophylaxis is only rarely prescribed to these patients. Recent randomized, controlled trials proved the therapeutic effects of hormone replacement therapy, as well as of bisphosphonates and active vitamin D analogs in primary and secondary prevention of glucocorticoid-induced osteoporosis.

AB - Chronic glucocorticoid treatment is the most frequent cause of secondary osteoporosis. The direct inhibitory effect of glucocorticoids on osteoblasts results in decreased bone formation. Increased osteoclastic bone resorption due to low concentrations of gonadal steroid hormones and glucocorticoid-induced direct suppression of intestinal calcium absorption also contribute to the decrease of bone mass in these patients. Bone loss is rapid, particularly in the first months of glucocorticoid therapy. Bone mineral density of the lumbar spine and proximal femur should be measured in patients who are starting chronic therapy with glucocorticoids. Although glucocorticoid-induced osteoporosis is a severe and nowadays partially preventable disorder, osteoporosis prophylaxis is only rarely prescribed to these patients. Recent randomized, controlled trials proved the therapeutic effects of hormone replacement therapy, as well as of bisphosphonates and active vitamin D analogs in primary and secondary prevention of glucocorticoid-induced osteoporosis.

UR - http://www.scopus.com/inward/record.url?scp=0034731685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034731685&partnerID=8YFLogxK

M3 - Article

C2 - 10697979

AN - SCOPUS:0034731685

VL - 141

SP - 219

EP - 223

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 5

ER -